Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 9, Issue 1, pp. 50-61
PubMed
Published By
Print ISSN
Online ISSN
History
- Received February 13, 2020
- Revision received August 5, 2020
- Accepted November 4, 2020
- Published first November 11, 2020.
Article Versions
- Previous version (November 11, 2020 - 05:59).
- Previous version (December 14, 2020 - 05:53).
- You are viewing the most recent version of this article.
Copyright & Usage
©2020 American Association for Cancer Research.
Author Information
- Iris de Weerdt1,2,
- Roeland Lameris1,
- George L. Scheffer1,
- Jana Vree1,
- Renate de Boer2,
- Anita G. Stam1,
- Rieneke van de Ven1,
- Mark-David Levin3,
- Steven T. Pals4,5,
- Rob C. Roovers6,
- Paul W.H.I. Parren6,7,
- Tanja D. de Gruijl1,
- Arnon P. Kater2,5, and
- Hans J. van der Vliet1,6,*
- 1Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam Infection and Immunity Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
- 2Department of Hematology, Cancer Center Amsterdam, Amsterdam Infection and Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
- 3Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands.
- 4Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
- 5Lymphoma and Myeloma Center Amsterdam (LYMMCARE), Amsterdam, the Netherlands.
- 6Lava Therapeutics, Utrecht, the Netherlands.
- 7Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands.
- ↵*Corresponding Author:
Hans J. van der Vliet, Lava Therapeutics, Yalelaan 60, 3584 CM, Utrecht, the Netherlands. E-mail: h.vandervliet{at}lavatherapeutics.com or jj.vandervliet{at}amsterdamumc.nl
January 2021
Volume 9, Issue 1
Volume 9, Issue 1
A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell–Mediated Antitumor Responses in Human B-cell Malignancies
Jump to section
Advertisement